Editor-in-Chief Hatice Kübra Elçioğlu Vice Editors Levent Kabasakal Esra Tatar Online ISSN 2630-6344 Publisher Marmara University Frequency Bimonthly (Six issues / year) Abbreviation J.Res.Pharm. Former Name Marmara Pharmaceutical Journal
Journal of Research in Pharmacy 2023 , Vol 27 , Issue 6
Evaluation of conventional karyotyping, lactate dehydrogenase levels, white blood cell count, and bone marrow blast percentage as good prognostic tests in patients with acute lymphoblastic leukemia
Abdulkader MEMEH1,Abduljalil GHRIWATI1,Ibrahim Kebbe WAR2,Khalid KHANJI4
1Department of Biotechnology Engineering, Faculty of Technology, Aleppo University, Aleppo, Syrian Arab Republic
2Department of Biochemistry and Clinical, Faculty of Pharmacy, Ebla Private University, Aleppo, Syrian Arab Republic
3Department of Hematology, Faculty of Medicine, Aleppo University, Aleppo, Syrian Arab Republic
DOI : 10.29228/jrp.522 Acute lymphoblastic leukemia is a specific type of hematologic neoplasm in which outcomes may be affected by many variables such as the patient's age, gender, conventional karyotyping reports, lactate dehydrogenase concentration, and white blood cell count at diagnosis. The aim of this study was to assess the prognostic significance of those factors on the overall survival of patients diagnosed with ALL. The current study includes 65 patients diagnosed with ALL who were tested for cytology, conventional karyotyping, and immunophenotyping. The results of the current study have indicated the average patient’s age was 14 years old. In addition, around 47.7% of patients had chromosomal abnormalities. Furthermore, the patients with LDH levels higher than 450 IU/L, and WBC counts over 100 X109 (Cell /L) had a shorter overall survival in month compared to other groups. However, the results suggested that conventional karyotyping, LDH, and WBC count might be used as good prognostic tests in patients with ALL at diagnosis. Keywords : Acute lymphoblastic Leukemia, Conventional Karyotyping, LDH, WBC
Marmara University